SEC Filing Summary: Coeptis Therapeutics Holdings, Inc. (COEP)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing cell therapy technologies for cancer and other diseases. The company operates as a holding company with subsidiaries including Coeptis Therapeutics, Inc., SNAP Biosciences Inc., and GEAR Therapeutics Inc. It is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | As of June 30, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(3,035,345) | $(6,036,733) | N/A |
| Loss Per Share (Basic & Diluted) | $(0.08) | $(0.17) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $1,555,075 |
| Total Assets | N/A | N/A | $4,198,420 |
| Total Liabilities | N/A | N/A | $4,508,480 |
| Stockholders' Equity (Deficit) | N/A | N/A | $(310,060) |
| Notes Payable (Current) | N/A | N/A | $1,553,929 |
| Notes Payable (Long-Term) | N/A | N/A | $150,000 |
Note: The company reported no revenue for the periods presented. Operating expenses totaled $2,828,102 for the quarter and $5,750,485 for the six-month period.
Material Changes vs. Prior Period
- Operating Expenses: Decreased significantly from $3,684,984 in Q2 2023 to $2,828,102 in Q2 2024, primarily due to lower professional services expenses related to equity transactions.
- Net Loss: Improved slightly on a quarterly basis (from $(3.2M) to $(3.0M)) and significantly on a six-month basis (from $(11.2M) to $(6.0M)).
- Derivative Liability: The fair value of warrant liabilities increased by $114,375 during the six months ended June 30, 2024, resulting in a non-cash loss.
- Capital Structure: The company completed an initial closing of a Series A Preferred Stock offering in June 2024, raising $4.3 million. Additionally, $7.6 million in subscription receivables is recorded as a contra-equity account.
- Debt: Current notes payable increased from $975,000 at year-end 2023 to $1,553,929, reflecting new borrowings and extensions of maturity dates.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the company's accumulated deficit of $93.4 million and net losses raise substantial doubt about its ability to continue as a going concern. Management plans to raise additional capital through equity or debt sales to sustain operations.
- Revenue Outlook: Management does not expect to generate significant revenue for at least the next two years while drug development continues.
- Strategic Focus: The company is focusing on co-development partnerships, specifically with Vy-Gen Bio (CD38-GEAR-NK and CD38-Diagnostic) and Deverra Therapeutics (NK cell therapy platform). Previous commercial products (anti-hypertension) have been abandoned.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to self-identified material weaknesses in internal accounting personnel and financial statement close processes.
- Subsequent Events: A second closing of the Series A offering occurred on July 31, 2024, raising an additional $1.3 million. On August 12, 2024, $5.7 million of subscription receivables were satisfied via issuance of common stock in two privately held companies.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $1.55 million cash balance against the $1.55 million in current notes payable due within 12 months.
- Subscription Receivables: Confirm the collectability of the $7.6 million subscription receivable balance, which is currently recorded as a contra-equity item.
- Series A Offering Terms: Review the specific conversion terms, beneficial ownership limitations, and liquidation preferences of the newly issued Series A Preferred Stock.
- Internal Control Remediation: Assess the timeline and plan for remedying the material weaknesses in internal controls over financial reporting.
- Debt Maturities: Monitor the repayment or extension status of the $1.55 million in current notes payable, several of which have been extended multiple times.